Pelage Pharmaceuticals
- Biotech or pharma, therapeutic R&D
Pelage is a clinical-stage regenerative medicine biotech developing first-in-class treatments for hair loss. The lead asset, PP405, is a novel topical small molecule targeting a mitochondrial transporter to directly activate hair follicle stem cells and induce hair growth. It is currently in phase 2 clinical trials in men and women with androgenetic alopecia. Pelage's series A and series A-1 were led by GV.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}